Mayo Clinic researchers, collaborating with Stanford Medicine over eight years, unveiled an artificial intelligence framework that can use a blood biopsy to detect tumor microenvironment features across multiple cancer types. The approach—described by Dr. Aadel Chaudhuri as a potential paradigm shift—leverages AI to extract signals from minimally invasive blood tests that traditionally required tissue sampling, offering a scalable route to profiling immune and stromal factors that influence treatment response.
If validated in larger clinical studies and cleared for clinical use, the technology could expand precision oncology to underrepresented and hard-to-biopsy patient populations, guide therapy selection, monitor response and resistance, and streamline clinical-trial enrollment. The development highlights growing intersections between AI, liquid biopsy diagnostics and oncology care, while underscoring needs for rigorous validation, regulatory review and integration into clinical workflows before broad adoption.
